An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Relapsed or Refractory Multiple Myeloma With Repeated Administration in Patients With Clinical Benefit
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Nintedanib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 14 Jul 2014 New trial record